Navigation Links
NuVasive to Present at Canaccord Adams Musculoskeletal Conference
Date:2/17/2009

SAN DIEGO, Feb. 17 /PRNewswire-FirstCall/ -- NuVasive, Inc. (Nasdaq: NUVA), a medical device company focused on developing products for minimally disruptive surgical treatments for the spine, announced today that Patrick Williams, Vice President, Finance, is scheduled to present at the Canaccord Adams Musculoskeletal Conference at the University of Nevada in Las Vegas, Nevada on Tuesday, February 24, 2009 at 8:20 a.m. PT.

A live Web cast of the presentation will be available online from the investor relations page of the Company's corporate Web site at www.nuvasive.com. After the live Web cast, the presentation will remain available on NuVasive's Web site, www.nuvasive.com, for 30 days.

About NuVasive

NuVasive is a medical device company focused on the design, development and marketing of products for the surgical treatment of spine disorders. The Company's product portfolio is focused on applications in the over $4.6 billion U.S. spine fusion market. The Company's current principal product offering includes a minimally disruptive surgical platform called Maximum Access Surgery, or MAS(R), as well as a growing offering of cervical and motion preservation products.

The MAS platform offers advantages for both patients and surgeons such as reduced surgery and hospitalization time and faster recovery. MAS combines three categories of current product offerings: NeuroVision(R) a proprietary software-driven nerve avoidance system; MaXcess(R) a unique split-blade design retraction system; and specialized implants, like SpheRx(R) and CoRoent(R), that collectively minimize soft tissue disruption during spine surgery while allowing maximum visualization and surgical reproducibility. NuVasive's product offering is also focused on cervical internal fixation products and its R&D pipeline emphasizes both MAS and motion preservation. NuVasive's Biologic product portfolio includes FormaGraft(R), Osteocel(R) Plus, and the Progentix products, all of which are intended to facilitate fusion and complement the core fixation products.

NuVasive cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties that could cause actual growth and results to differ materially include, but are not limited to: the uncertain process of seeking regulatory approval or clearance for NuVasive's products or devices, including risks that such process could be significantly delayed; the possibility that the FDA may require significant changes to NuVasive's products or clinical studies; the risk that products may not perform as intended and may therefore not achieve commercial success; the risk that competitors may develop superior products or may have a greater market position enabling more successful commercialization; the risk that additional clinical data may call into question the benefits of NuVasive's products to patients, hospitals and surgeons; and other risks and uncertainties more fully described in NuVasive's press releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.

    Contact:                            Investors:
    Kevin C. O'Boyle                    Patrick F. Williams
    EVP & Chief Financial Officer       Vice President, Finance
    NuVasive, Inc.                      NuVasive, Inc.
    858-909-1998                        858-638-5511
    investorrelations@nuvasive.com      investorrelations@nuvasive.com

    Media:
    Jason Rando
    The Ruth Group
    646-536-7025
    jrando@theruthgroup.com


'/>"/>
SOURCE NuVasive, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. NuVasive to Present at ROTH 21st Annual OC Growth Stock Conference
2. NuVasive Announces Preliminary Unaudited Full Year 2008 Financial Results
3. NuVasive to Present at 27th Annual J.P. Morgan Healthcare Conference
4. NuVasive to Present at 20th Annual Piper Jaffray Health Care Conference
5. NuVasive Announces Patent Infringement Complaint Brought by Medtronic Sofamor Danek
6. NuVasive to Present at Goldman Sachs 29th Annual Global Healthcare Conference
7. NuVasive Acquires First Stem Cell Bone Graft Substitute
8. NuVasive Reports First Quarter 2008 Financial Results
9. NuVasive Prices $200 Million Convertible Senior Notes Due 2013
10. NuVasive to Offer $200 Million Convertible Senior Notes Due 2013
11. NuVasive Announces Preliminary Unaudited Full Year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... ... September 25, 2017 , ... ... and efficiency. The principle of First-Defect-Stop for laboratory weighing is designed ... have the chance to have negative consequences on downstream processes. , If a ...
(Date:9/25/2017)... (PRWEB) , ... September 25, 2017 , ... Physician Partners ... Fla. location at 5304 Main Street as an interventional pain management specialist. , ... and extremities. He joins PPOA from private practice In Brooksville, Fla. His orthopedic background ...
(Date:9/25/2017)... ... ... “Renew Refresh Restore Reward”: is a story of struggle and how trouble often happens ... Freeman, cofounded the Free Spirit Bible Church and currently serves as the church’s Director ... us to come over before the baby had to go back to her grandparents. ...
(Date:9/25/2017)... ... September 25, 2017 , ... The trend-spotters, tastemakers, and healthy lifestyle product experts ... based super herb drinks, with the new NEXTY Gold Award at the Natural Products ... the NEXTY Gold, which is reserved for just those companies that hit high marks ...
(Date:9/24/2017)... ... September 25, 2017 , ... Bhowanie Benimadhu’s new book “ Our ... questions of life and seeks answers in both Eastern and Western religious traditions and ... God is in the mind of humankind for the past thousands of years and ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... 6, 2017  Robert G. Szewc, M.D., is recognized ... in recognition of his contributions to the Medical field.  ... Nephrologist at the practice of Kidney and Hypertension Specialists, ... and hypertension solutions. He has worked in this position ... experience, as well as expertise in kidneys, hypertension, chronic ...
(Date:9/6/2017)...   PDI , a leader in infection prevention ... educational session focused on the role of chlorhexidine gluconate ... the 2017 Annual Scientific Meeting of the Association for ... the Phoenix Convention Center in ... will also feature PDI,s Prevantics® Device Swab ...
(Date:9/6/2017)... , Sept. 6, 2017 Eli Lilly and ... will present new data for galcanezumab and lasmiditan, two ... the International Headache Society (IHC) taking place Sept. 7-10 ... Lilly will highlight new, long-term data from an open-label ... of galcanezumab (120 mg and 240 mg) for the ...
Breaking Medicine Technology: